Skip to main content
IONS logo

IONS · Ionis Pharmaceuticals Inc

Track IONS — free
$26.96 -1.05 (-3.75%) At close · Nov 17
Market Cap
$4.49B
Shares
166.55M
Volume · Nov 17 4.49M Avg daily vol (3M) 3.9M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$26.96 Open$28.09 Day$26.55–28.09 52W close$26.96–86.50 Avg vol 30d4.2M Short int21.2M · 12.7% of shares · 8.4d Short vol52% Last earningsNov 9, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 9

Up next

Feb 24, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 9
Earnings call
Tringolza net product sales guidance cut to about $50 million

Ionis lowered its 2026 Tringolza net product sales guidance to approximately $50 million, citing a more gradual launch ramp. It kept total revenue guidance at $875 million to $900 million and now expects cash flow break-even in 2029.

4 source passages
As Brett mentioned, we are lowering our full-year Tringolza net product sales guidance to approximately $50 million. For Tringolza, we are lowering our 2026 full-year revenue guidance to approximately $50 million to reflect a more gradual launch ramp than we had anticipated. Our year-to-date results and fourth-quarter outlook keep us on track to achieve our 2026 total revenue of $875 million to $900 million we do expect the timing to shift from 2028 to 2029. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue grows while nine-month net loss more than doubles

Ionis Pharmaceuticals reported nine-month 2026 revenue of $756.8 million, up from $740.4 million, while net loss widened to $317.1 million from $152.0 million. Eplontersen and pelacarsen Phase 3 trials missed primary endpoints; ulefnersen and sefaxersen reported positive Phase 3 results.

Revenue $242.72M ▲ 54.9% Net loss $109.97M Diluted EPS -$0.66
Read from the MD&A section
6 source passages
Total revenue for the three and nine months ended September 30, 2026 was $242.7 million and $756.8 million, respectively, compared to $156.7 million and $740.4 million for the same periods in 2025 respectively Net loss | (110.0) | (128.6) | (317.1) | (152.0) In July 2026, we and AstraZeneca announced that the CARDIO-TTRansform trial for eplontersen in patients with ATTR-CM missed the primary efficacy endpoint of the composite outcome of cardiovascular, or CV, mortality and recurrent CV clinical events up to Week 140 compared with placebo. In September 2026, Novartis announced that the pelacarsen Phase 3 Lp(a)HORIZON study did not meet its primary endpoint of reducing the risk of cardiovascular events compared to placebo. In September 2026, we and Roche announced positive interim data from the ongoing Phase 3 IMAgINATION study evaluating investigational sefaxersen in adults with primary IgAN, which were presented in October 2026 at the American Society of Nephrology, or ASN. In September 2026, we and Otsuka announced positive topline results from the Phase 3 FUSION study of ulefnersen in juvenile and adult patients with FUS-ALS. Open the document at this passage
Nov 9
Current report 8-K
TRYNGOLZA sales guidance lowered to ~$50 million

Ionis Pharmaceuticals lowered TRYNGOLZA 2026 product sales guidance to ~$50 million from $100-110 million after a more gradual launch ramp, while reaffirming 2026 total revenue guidance of $875-900 million.

Financial results
4 source passages
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the third quarter ended September 30, 2026. Full year 2026 product sales guidance lowered to approximately $50 million, reflecting a more gradual launch ramp than anticipated as Ionis establishes a new treatment paradigm for people with sHTG TRYNGOLZA product sales, net | $100-110 million | ~$50 million Total Revenue | $875-900 million | Unchanged Open the document at this passage
Oct 23
Current report 8-K
Regulation FD disclosure, Other events

Ionis Pharmaceuticals said Roche’s Phase 3 IMAgINATION data showed investigational sefaxersen reduced proteinuria by 43.1% versus placebo at 37 weeks, with greater hematuria resolution and no new safety signals.

Oct 21
Current report 8-K Events of Oct 20
Regulation FD disclosure, Other events

FDA approved GSK’s HIBSAGO™ (bepirovirsen) for specified adults with chronic hepatitis B; Phase 3 B-Well trials showed 19% functional cure, and Ionis Pharmaceuticals Inc is eligible for tiered royalties of 10-12% on net sales.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$960.09M
Trailing 12 months
Net income (TTM)
−$546.54M
Trailing 12 months
Revenue growth YoY
+54.9%
Year over year
Operating margin
-58.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-13.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$917.32M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.0%
Year over year · more shares
Price change (1Y)
-63.2%
Trailing year
Short interest
12.7%
Latest settlement · 8.4 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 9, 2026
Q3 FY26

TL;DR. Ionis reported revenue growth of 55% in Q3 excluding a one-time 2025 payment and reaffirmed its total revenue guidance. However, it cut TRYNGOLZA 2026 product sales guidance to about $50 million and shifted cash-flow break-even to 2029 from 2028.

Bullish
  • + Total revenue rose 55% in Q3 and 64% for nine months, excluding a one-time 2025 payment. new
  • + DAWNZERA generated $37 million of U.S. net product sales in Q3 and continues to gain momentum. new
  • + Total R&D revenue rose to $107 million in Q3 from $41 million a year earlier. new
  • + ZANVASTRO's first patients have received commercial treatment after launch. new
  • + Hibsago approved in the U.S. and Japan for chronic hepatitis B. new
  • + Total 2026 revenue guidance of $875-900 million is reaffirmed. new
Bearish
  • − TRYNGOLZA 2026 product sales guidance cut to about $50 million from $100-110 million. new
  • − CARDIO-TTRansform missed its primary composite endpoint in the overall population.
  • − Cash fell to $1.9 billion from $2.7 billion at year-end 2025. new
  • − Cash-flow break-even timing shifted to 2029 from 2028. new
  • − A majority of TRYNGOLZA prescriptions required a medical exception early in the launch. new
  • − Two recent Phase 3 readouts did not deliver the outcomes management hoped for. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 25.5 · fear Equity put/call 0.71
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −58%
below
Price vs 50-day avg −37%
below
RSI (14) 22
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −41%
trailing
6-month return −65%
trailing
YTD return −66%
this year
Relative strength −62%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $42 › 200d $64 — 200d above 50d
Institutional flow Distributing
-11% holders QoQ · +61 funds added
Insider flow Accumulating
Net +$86.8K over 90 days · 67% sells
Short interest Rising
12.71% of shares out · ▲ +2.5% MoM · 8.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
468 holders — mid 3-yr range
Squeeze score 70
high risk · 0–100
Fundamentals
Strong
Revenue growth +46%
Y/Y
EPS growth +22%
Y/Y
Free cash flow $-320.0M
Buyback $125.0M
authorized
Balance sheet $1.4B
net debt
Quant / Vol
risk profile
Very High
Volatility 49%
annualized · 1-yr
Max drawdown −69%
past year
ATR 8.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 6 of last 6
Latest guidance · from the Earnings Call filed Nov 9, 2026
full-year 2026
Tringolza net product sales $50M
2026
Total revenue Maintained $875M – $900M
Jul 29, 2026 $875M – $900M changed to Nov 9, 2026 $875M – $900M
prior FY $943.71M midpoint −6.0% Y/Y
Donzera net product sales $110M – $120M
year-end 2026
Year-end cash balance at least $1.6B
Previous outlook earlier release · from the 8-K filed Apr 29, 2026

Still-open targets the latest release did not restate under the same label.

Cash, cash equivalents and short-term investments · Full Year 2026 at least $1.6B
DAWNZERA product sales, net · Full Year 2026 $110M – $120M
Guided vs delivered · last 6 settled
Total Revenue Full Year 2025
guided $875M – $900M
$943.71M Beat +6.3%
Revenue Full Year 2024
guided at least $575M
$705.14M In line
Revenue Full Year 2023
guided at least $575M
$787.65M In line
Revenue Full Year 2022
guided at least $575M
$587.37M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−58% Bearish
Price vs 50-day avg
−37% Bearish
RSI (14)
22 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $42 › 200d $64 — 200d above 50d
Institutional flow Distributing
-11% holders QoQ · +61 funds added
Insider flow Accumulating
Net +$86.8K over 90 days · 67% sells
Short interest Rising
12.71% of shares out · ▲ +2.5% MoM · 8.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
468 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $27 Now $27 · 0% Range high $87
vs 200-day avg -58% vs 50-day avg -37%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IONS
Ionis Pharmaceuticals Inc
this stock
$4.49B -65.9% +46.5% — 12.7%
VRTX
Vertex Pharmaceuticals Inc
$135.44B +17.8% +46.2% 34.4 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$99.08B +24.1% +20.8% 21.2 2.1%
MRNA
Moderna, Inc.
$83.68B +601.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$64.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
468
% held
105.9%
Net QoQ
-3.5M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
471
View
Short & Settlement
Short Interest Rising
Shares short
21.2M
Days to cover
8.4d
Change
+512.8K sh
View
Short Volume
Short vol %
52%
As of
Nov 17, 2026
Short Total
View
Fails to Deliver
FTD shares
879
Value
$37.7K
As of
Oct 26, 2026
View
Off-Exchange
Off-exchange %
35.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$86.8K
Buyers / Sellers
1 / 2
Buyers Sellers
View
Congressional Trades Sell
Member
Daniel Goldman
Amount
$1.0K–$15.0K
Traded
Mar 6, 2023
View
Financials
Financials
Revenue (FY)
$943.7M
Net income (FY)
$-381.4M
EPS diluted
$-2.38
View
Buybacks
Authorized
$125.0M
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 9, 2026
This year
31

Ionis Pharmaceuticals lowered TRYNGOLZA 2026 product sales guidance to ~$50 million from $100-110 million after a more gradual launch ramp, while reaffirming 2026 total revenue guidance of $875-900 million.

View
Proposed Sales
Value
$59.7K
Shares
1.4K
Filed
Oct 16, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 9, 2026
View
Investor Relations
Latest news
Ionis to hold third quarter 2026…
Published
Nov 2, 2026
View

Performance

5D 20D 120D MTD YTD
IONS -4.4% -40.6% -65.1% -38.1% -65.9%
SPY -2.3% -4.8% -2.9% -3.1% +7.4%
vs SPY -2.0% -35.9% -62.2% -35.0% -73.3%

Capital returns

Buyback program · as of Sep 30, 2019
Authorized
$125.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 874015 CUSIP 462222100 13F (30d) 483 filings 437 filers Visit website Investor relations